Fresenius completed mAbxience deal as Fresenius stock trades 1.05 percent higher

Published on 10/14/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius bought 45 percent of mAbxience for EUR 750 million on October 1, 2026. Fresenius stock costs EUR 43.25, 1.05 percent above EUR 42.80.

Biosimilar ownership and earnings

Fresenius acquired the remaining 45.00 percent of mAbxience for up to EUR 750.00 million on October 1, 2026.
Second-quarter 2026 revenue reached EUR 5.864 billion, up 6.00 percent year over year.
Fresenius stock traded at EUR 43.25 at 1:39 p.m. CEST at Lang & Schwarz on October 14, 2026, 1.05 percent above the Xetra close of October 13, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) was trading at EUR 43.25 at Lang & Schwarz at 1:39 p.m. CEST on October 14, 2026, 1.05 percent above the Xetra close of October 13, 2026 at EUR 42.80. The company completed its purchase of the remaining 45.00 percent of mAbxience for up to EUR 750.00 million on September 30, 2026, as EQS News reported on October 1, 2026.

Three strategic milestones

Fresenius reported on its investor-relations page that second-quarter 2026 revenue rose 6.00 percent year over year to EUR 5.864 billion. EBIT before special items increased 10.00 percent to EUR 719.00 million, while core net income rose 14.00 percent to EUR 470.00 million.

The acquisition gives Fresenius full ownership of a biosimilars platform with four marketed products and eight development candidates. The company said the transaction should contribute immediately to group core earnings per share, while net debt to EBITDA is expected to rise by approximately 20 basis points.

What does full ownership change?

The strategic value lies in control over manufacturing capacity, investment decisions and launch timing. Fresenius said mAbxience generated more than EUR 320.00 million in revenue in fiscal year 2025, and the platform operates three production facilities in Spain and Latin America.

Analyst views provide a second benchmark. FinanzNachrichten reported on September 17, 2026 that UBS kept a Buy rating and a EUR 56.00 target. The target lies 29.48 percent above the Lang & Schwarz price. FinanzNachrichten reported on October 5, 2026 that Jefferies maintained Buy with a EUR 55.00 target.

Dates for the next report

Fresenius lists November 4, 2026 as the next publication date for its third-quarter 2026 financial report. The date places the next earnings update ahead of the company's full-year outlook cycle and gives investors a scheduled point for assessing the mAbxience integration and the Helios reorganization.

Stock stays above EUR 43

The current Lang & Schwarz quote of EUR 43.25 is 1.05 percent above the Xetra close of EUR 42.80 from October 13, 2026. The reference price remains below the 52-week high of EUR 52.96 and above the 52-week low of EUR 35.11.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.